Wikipedia
Abemaciclib
Abemaciclib (previously known as LY2835219) is a CDK inhibitor selective for CDK4 and CDK6. It is an investigational drug for various types of cancer developed by Eli Lilly. It was designated as a breakthrough therapy by the U.S. Food and Drug Administration in October 2015.